ESR1 and breast carcinoma: We chose these two datasets because of their large sample sizes, recent data (published in 2018 and 2022, respectively), complete and detailed clinical annotations, and consistent data collection, which together provide a strong foundation for comprehensive and up-to-date research on ER+ breast cancer outcomes with hormone therapy.